...Kong and Macau.FDA approves GSK’s Trelegy Ellipta for asthmaOn Wednesday, FDA approved an sNDA for Trelegy Ellipta umeclidinium bromide/fluticasone furoate/vilanterol...
...from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) is the first LABA/LAMA/inhaled corticosteroid combination approved for the indication. Trelegy Ellipta...

...app. If approved, Novartis’ combos would be the first triple therapies approved for asthma. Trelegy Ellipta umeclidinium bromide/fluticasone furoate/vilanterol...

...Pulmonary-Allergy Drugs Advisory Committee to discuss an sNDA from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) for Trelegy Ellipta fluticasone furoate/umeclidinium/vilanterol...

...Advisory Committee will hold a meeting on April 21 to discuss an sNDA for Trelegy Ellipta fluticasone furoate/umeclidinium/vilanterol...
...bmn 270) Descovy (Brand), emtricitabine/tenofovir alafenamide (Generic), F/TAF (Informal), Descovy (Other) Truvada, emtricitabine/tenofovir elafibranor (GFT505) Trelegy Ellipta, Umeclidinium bromide/fluticasone furoate/vilanterol, Fluticasone furoate/vilanterol/umeclidinium, fluticasone furoate/umeclidinium/vilanterol, FF/UMEC/VI...

...in Phase III GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Innoviva Inc. (NASDAQ:INVA) said once-daily Trelegy Ellipta fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI...
...member 17; SOD1 - Superoxide dismutase 1 Brian Moy, Assistant Editor bb2121 BIIB067, IONIS-SOD1Rx GKT831, gkt137831 Trelegy Ellipta, Umeclidinium bromide/fluticasone furoate/vilanterol, Fluticasone furoate/vilanterol/umeclidinium, fluticasone furoate/umeclidinium/vilanterol, FF/UMEC/VI...

...neuropathy (LHON) Additional phase III data 2Q19 GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) / Innoviva Inc. (NASDAQ:INVA) Trelegy Ellipta...

...to Support Nucala for COPD" ). GSK's asthma franchise includes established programs Trelegy Ellipta, Umeclidinium bromide/fluticasone furoate/vilanterol and Fluticasone furoate/vilanterol/umeclidinium...

...Trelegy Ellipta fluticasone furoate/umeclidinium/vilanterol for maintenance treatment of chronic obstructive pulmonary disease (COPD). In September, FDA approved Trelegy Ellipta...
...at constant exchange rates from 3Q16, and just shy of the £7.88 billion consensus estimate. Chris Lieu Shingrix Trelegy Ellipta GlaxoSmithKline...

...Benlysta belimumab to treat systemic lupus erythematosus (SLE) GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) FDA approves Trelegy Ellipta fluticasone furoate/umeclidinium/vilanterol...

...IMPACT trial in 10,355 chronic obstructive pulmonary disease (COPD) patients showing that once-daily Trelegy Ellipta fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI...
...Trelegy Ellipta is the first once-daily single inhaler triple therapy approved for COPD in the U.S. Trelegy Ellipta...
...Inc. (NASDAQ:INVA), South San Francisco, Calif. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Trelegy Ellipta fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI...